Caractérisation pathologique et moléculaire des adénocarcinomes pulmonaires multiples synchrones et des patients atteints de DIPNECH


Philippe Joubert

Institut universitaire de cardiologie et de pneumologie de Québec [IUCPQ]


Domaine : cancer

Programme Chercheurs-boursiers cliniciens - Junior 1

Concours 2018-2019

Lung cancer is the deadliest cancer in Canada accounting for more deaths than breast, prostate and colon cancers combined. Unfortunately, more than two thirds of patients present with advanced disease, limiting the possibility of a curative surgical treatment. The only remaining therapeutic options rely on systemic treatments, with limited success, as evidenced by a survival of less than 20% at five years. Improving the therapeutic arsenal is therefore urgently needed to improve the management of patients with a malignant lung neoplasm. During the last decade, physicians and researchers have become increasingly aware that all cancers are not the same. Rather, different types contain specific genetic mutations that affect how they progress and respond to therapies. In lung cancer, the identification of recurrent genetic alterations and use of selective inhibitors targeting these mutations have led to the development of personalized medicine and renewed hope to significantly extends the life expectancy of the patients.

My research program focuses on the presence of genetic alterations in very important but poorly characterized subsets of malignant lung tumours and for which the actual treatments do not provide significant benefits. More specifically, I study the presence of molecular alterations in multiple synchronous lung adenocarcinomas, a common subtype of lung adenocarcinoma presenting with multiple lesions disseminated throughout the lungs. I am also interested to understand the genetic events that drive the onset of a respiratory disease affecting middle-age women and characterized by diffuse proliferation of neuroendocrine tumours, and for which there is actually no treatment. In order to achieve my goals, I will take advantage of the wealth of our unique biobank, as well as the expertise of the Quebec Heart and Lung Institute in pathology and respiratory oncology.